<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: <z:hpo ids='HP_0002621'>Atherosclerosis</z:hpo> and <z:hpo ids='HP_0002634'>arteriosclerosis</z:hpo> are mainly caused by the dysfunction of arterial components, namely, vascular endothelial cells, smooth muscle cells, and the extracellular matrix </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">Endothelial dysfunction</z:e> is well established as a predictive surrogate marker of cardiovascular events; however, little is known regarding the clinical implications of vascular smooth muscle dysfunction for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> and <z:e sem="disease" ids="C0155765" disease_type="Disease or Syndrome" abbrv="">microangiopathy</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we aimed to clarify the association of arterial dysfunction with micro-/<z:e sem="disease" ids="C1096293" disease_type="Disease or Syndrome" abbrv="">macroangiopathy</z:e> and conventional <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> in 181 type 2 diabetic patients (T2DM; age ± SD, 64 ± 10 years; duration of <z:mp ids='MP_0002055'>diabetes</z:mp>, 12 ± 10 years) </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Flow-mediated <z:mpath ids='MPATH_66'>dilatation</z:mpath> (FMD) and <z:chebi fb="0" ids="28787">nitroglycerin</z:chebi>-mediated <z:mpath ids='MPATH_66'>dilatation</z:mpath> (NMD) were assessed to evaluate <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> and vascular smooth muscle dysfunction, respectively, by using a novel ultrasound device, UNEXEF18G (Unex Co </plain></SENT>
<SENT sid="4" pm="."><plain>Ltd., Japan) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The FMD and NMD were 6.4 ± 3.9% and 13.4 ± 6.6%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>No significant differences in FMD were noted between T2DM with and without micro- or <z:e sem="disease" ids="C1096293" disease_type="Disease or Syndrome" abbrv="">macroangiopathy</z:e>; however, NMD in T2DM patients with micro- and <z:e sem="disease" ids="C1096293" disease_type="Disease or Syndrome" abbrv="">macroangiopathy</z:e> was significantly lower than that in T2DM patients without <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">angiopathy</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>NMD decreased with the progression of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> (CKD) stage (p = 0.005), but not FMD (p = 0.071) </plain></SENT>
<SENT sid="8" pm="."><plain>On multiple regression analysis, significant independent contributors to FMD were age, smoking, systolic blood pressure, glycosylated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, and serum total cholesterol, while those for NMD were age, systolic blood pressure, and waist circumference </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The relationship of vascular complications and <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> with NMD is different from that with FMD in type 2 diabetic patients </plain></SENT>
</text></document>